Generated by AI
Zymeworks Inc. is a biotechnology company focused on discovering, developing, and commercializing multifunctional biotherapeutics for cancer and other serious diseases. The company operates across therapeutic areas including oncology, inflammation, and autoimmune disease, using proprietary antibody-based platforms to design differentiated drug candidates. Its current portfolio includes clinical-stage programs and licensed healthcare assets, supported by integrated research, development, and commercialization capabilities. Zymeworks also works with antibody-drug conjugate technologies and other advanced biologic platforms aimed at improving precision and therapeutic performance across difficult-to-treat conditions. With operations centered on modern drug innovation, Zymeworks Inc. plays a role in advancing next-generation treatments within the global biopharmaceutical market.
Website108 Patriot Drive
Middletown, DE, 19709
United States
The latest articles about ZYME.
Summary of Oct 24's posts. Generated by AI.
Summary of Nov 17's posts. Generated by AI.
Summary of Oct 19's posts. Generated by AI.
Summary of Oct 23's posts. Generated by AI.
Investors talking about ZYME also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.